Clinical decision making is improved by BioFire Pneumonia Plus in suspected lower respiratory tract infection after lung transplantation : Results of the prospective DBATE‐IT * study

ORCID
0000-0003-1421-1426
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Kayser, Moritz Z.;
ORCID
0000-0001-7373-752X
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Seeliger, Benjamin;
ORCID
0000-0002-6641-7170
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Valtin, Christina;
ORCID
0000-0003-2926-3608
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Fuge, Jan;
Affiliation
Department of Microbiology and Hospital Hygiene Hannover Medical School Hannover Germany
Ziesing, Stefan;
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Welte, Tobias;
GND
123964334
ORCID
0000-0001-8157-2753
Affiliation
Institute for Infectious Diseases and Infection Control Jena University Hospital Jena Germany
Pletz, Mathias W.;
ORCID
0000-0001-9957-8571
Affiliation
Department of Microbiology and Hospital Hygiene Hannover Medical School Hannover Germany
Chhatwal, Patrick;
ORCID
0000-0002-9540-9022
Affiliation
Department of Respiratory Medicine Hannover Medical School Hannover Germany
Gottlieb, Jens

Background: Lower respiratory tract infections (LRTIs) are a significant cause of morbidity and mortality in lung transplant (LTx) recipients. Timely and precise pathogen detection is vital to successful treatment. Multiplex PCR kits with short turnover times like the BioFire Pneumonia Plus (BFPPp) (manufactured by bioMérieux) may be a valuable addition to conventional tests.

Methods: We performed a prospective observational cohort study in 60 LTx recipients with suspected LRTI. All patients received BFPPp testing of bronchoalveolar lavage fluid in addition to conventional tests including microbiological cultures and conventional diagnostics for respiratory viruses. Primary outcome was time‐to‐test‐result; secondary outcomes included time‐to‐clinical‐decision and BFPPp test accuracy compared to conventional tests.

Results: BFPPp provided results faster than conventional tests (2.3 h [2–2.8] vs. 23.4 h [21–62], p  < 0.001), allowing for faster clinical decisions (2.8 [2.2–44] vs. virology 28.1 h [23.1–70.6] and microbiology 32.6 h [4.6–70.9], both p  < 0.001). Based on all available diagnostic modalities, 26 (43%) patients were diagnosed with viral LRTI, nine (15 %) with non‐viral LRTI, and five (8 %) with combined viral and non‐viral LRTI. These diagnoses were established by BFPPp in 92%, 78%, and 100%, respectively. The remaining 20 patients (33 %) received a diagnosis other than LRTI. Preliminary therapies based on BFPPp results were upheld in 90% of cases. There were six treatment modifications based on pathogen‐isolation by conventional testing missed by BFPPp, including three due to fungal pathogens not covered by the BFPPp.

Conclusion: BFPPp offered faster test results compared to conventional tests with good concordance. The absence of fungal pathogens from the panel is a potential weakness in a severely immunosuppressed population.

Cite

Citation style:
Could not load citation form.

Rights

License Holder: © 2022 Wiley Periodicals LLC

Use and reproduction:
This publication is with permission of the rights owner freely accessible due to an Alliance licence and a national licence (funded by the DFG, German Research Foundation) respectively.